The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

The company is also developing a vaccine against a bacteria that causes urinary tract infections, bloodstream infections, and pneumonias, and testing approved drugs Cabenuva and Edurant in ...

The FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the virus at bay with a monthly injection instead of daily pill regimen. It follows a surprise ...

Almost everything is curable or treatable at this point…with PrEP, Doxy, HIV treatments (like Cabenuva) and testing so available, I want to encourage everyone who is active to take care of ...

Cabenuva grew 42%, driven by patient preference and proven and durable efficacy. CASM LATITUDE data presented at CROI and data from real-world cohorts that include over 10,000 people living with ...